Summary of the most important risk features defining high-risk patients with DLBCL already used in clinical practice or in clinical trials with corresponding survival parameters
| Risk factors . | High-risk features . | Survival . | References . |
|---|---|---|---|
| Clinical factors | IPI = 3; high-intermediate | 5-y OS (43%-67%) | 10,13 |
| IPI = 4, 5; high risk | 5-y OS (26%-53.9%) | 10,13 | |
| R-IPI = 3 (3-5 risk factors) | 4-y OS (55%-60.9%) | 11,13 | |
| NCCN-IPI = 6-8; high risk | 5-y OS (33%-49%) | 12,13 | |
| Biological factors | COO = ABC subtype | 5-y OS (35%-56%) | 14,15 |
| COO = type 3 unclassifiable | 5-y OS (39%-62%) | 14,15 | |
| DEL | 5-y OS (30%-40%) | 16-18 | |
| DHL/THL | 2-y OS (38%-82%) | 19-22 | |
| DHTsig+ | 5-y TTP 57% | 23 | |
| Biological factors: molecular taxonomy | MCD/C5/MYD88 | 5-y OS (26%-60%) | 24-26 |
| N1 | 5-y OS (27%-40%) | 24,27 | |
| A53/C2 | 5-y OS 63% (33%-100%) | 24-26 | |
| BN2/C1/NOTCH2 | 5-y OS 67% (38%-100%) | 24-27 | |
| EZB DHTsig+ MYC+ | 5-y OS (40%-48%) | 24-27 | |
| Radiomics prognostic factors: baseline and dynamic | ΔSUVmax < 66% at iPET2 | 2-y OS 54.2% | 28 |
| High TMTV > 328 cm3 and ΔSUVmax < 66% at iPET2 | 2-y OS 37.1% | 28 | |
| ECOG-PS ≥ 2 and TMTV > 220 cm3 | 4-y OS (41%-61%) | 29 | |
| High-risk IMIPI | 3-y OS 51.5% | 30 | |
| High-risk clinical PET model | 2-y PFS 48.6% | 31 | |
| ctDNA: baseline and dynamic | No EMR | 2-y EFS 50% | 32 |
| No MMR | 2-y EFS 46% | 32 |
| Risk factors . | High-risk features . | Survival . | References . |
|---|---|---|---|
| Clinical factors | IPI = 3; high-intermediate | 5-y OS (43%-67%) | 10,13 |
| IPI = 4, 5; high risk | 5-y OS (26%-53.9%) | 10,13 | |
| R-IPI = 3 (3-5 risk factors) | 4-y OS (55%-60.9%) | 11,13 | |
| NCCN-IPI = 6-8; high risk | 5-y OS (33%-49%) | 12,13 | |
| Biological factors | COO = ABC subtype | 5-y OS (35%-56%) | 14,15 |
| COO = type 3 unclassifiable | 5-y OS (39%-62%) | 14,15 | |
| DEL | 5-y OS (30%-40%) | 16-18 | |
| DHL/THL | 2-y OS (38%-82%) | 19-22 | |
| DHTsig+ | 5-y TTP 57% | 23 | |
| Biological factors: molecular taxonomy | MCD/C5/MYD88 | 5-y OS (26%-60%) | 24-26 |
| N1 | 5-y OS (27%-40%) | 24,27 | |
| A53/C2 | 5-y OS 63% (33%-100%) | 24-26 | |
| BN2/C1/NOTCH2 | 5-y OS 67% (38%-100%) | 24-27 | |
| EZB DHTsig+ MYC+ | 5-y OS (40%-48%) | 24-27 | |
| Radiomics prognostic factors: baseline and dynamic | ΔSUVmax < 66% at iPET2 | 2-y OS 54.2% | 28 |
| High TMTV > 328 cm3 and ΔSUVmax < 66% at iPET2 | 2-y OS 37.1% | 28 | |
| ECOG-PS ≥ 2 and TMTV > 220 cm3 | 4-y OS (41%-61%) | 29 | |
| High-risk IMIPI | 3-y OS 51.5% | 30 | |
| High-risk clinical PET model | 2-y PFS 48.6% | 31 | |
| ctDNA: baseline and dynamic | No EMR | 2-y EFS 50% | 32 |
| No MMR | 2-y EFS 46% | 32 |
Values in brackets refer to survival parameters in different patient cohorts described in the cited publications.